Machine Learning Enhances the Efficiency of Cognitive Screenings for Primary Care.

Background: Incorporation of cognitive screening into the busy primary care will require the development of highly efficient screening tools. We report the convergence validity of a very brief, self-administered, computerized assessment protocol against one of the most extensively used, clinician-administered instruments-the Montreal Cognitive Assessment (MoCA).

Method: Two hundred six participants (mean age = 67.

A systematic review of transition studies of pulmonary arterial hypertension specific medications.

Pulmonary arterial hypertension (PAH) is a progressive potentially fatal disease. Multiple pharmacologic options are now available, which facilitated transitions between different therapeutic options, although the evidence for such transitions has not been well described. We sought to review the evidence supporting the safety and/or efficacy of transitioning between PAH-specific medications.

Experiences of Children With Gay Fathers.

An online survey was distributed via snowball sampling and resulted in responses from 61 gay fathers raising children in 2 states. Fathers reported on the barriers they experienced and the pathways they took to becoming parents. They reported also on experiences of stigma directed at them and their children, especially from family members, friends, and people in religious institutions.

A State-Level Assessment of Hospital-Based Palliative Care and the Use of Life-Sustaining Therapies in the United States.

Background: It is unknown how the prevalence of hospitals with palliative care programs (PCPs) at the state level in the United States correlates with the treatment of critically ill patients.

Objective: We examined the relationship between state-level PCP prevalence and commonly used treatments for critically ill patients as well as other public health metrics.

Methods: We compiled state-level data for the year 2011 from multiple published sources.

Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.

Introduction: Recombinant human erythropoietin (rhEPO) is a first-line therapeutic for the anemia of chronic kidney disease, cancer chemotherapy, AIDS (Zidovudine therapy), and lower-risk myelodysplastic syndrome. However, rhEPO frequently elevates hypertension, is costly, and may affect cancer progression. Potentially high merit therefore exists for defining new targets for anti-anemia agents within erythropoietin (EPO) and EPO receptor (EPOR) regulatory circuits.